SOURCE: Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc.

April 04, 2011 10:26 ET

Therapeutic Solutions International, Inc. Announces Completion of Merger

SAN DIEGO, CA--(Marketwire - April 4, 2011) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today that the Company completed the merger with Splint Decisions Inc. on March 31, 2011. As part of the closing James P. Boyd, DDS, president and CEO of Splint Decisions, was appointed as Director of the Company and Director of Research and Product Development. 

Dr. Boyd has been best known for his work in the field of migraine prevention. His first patented medical device was the NTI Tension Suppression System, the first non-drug modality to be approved by the FDA for the prevention of medically diagnosed migraine pain.

"The merger of Therapeutic Solutions International, Inc. and Splint Decisions marks a major milestone in the growth plans of the Company," stated Dr. Boyd. "The current state of the economy has adversely affected the dental industry as much as any other. However, the needs of patients have not changed; in fact, those conditions associated with elevated stress are now even more prominent. It has become increasing difficult for a practitioner to meet their patients' needs while still running a successful business, so this is an exciting time for Therapeutic Solutions International to bring to the market, the "Total Splint Solution" ("TSS").

 The TSS is Dr. Boyd's latest developed product, which allows a dental practitioner to provide in a single visit, cost effective solutions to treat a variety of conditions such as bruxism, sleep apnea, and migraine.

Dr. Boyd is the past Director of Research and Senior Clinical Instructor at the White Memorial Medical Center Craniofacial/TMD clinic in Los Angeles and currently a practicing clinical consultant along side Andrew Blumenfeld, MD, (a neurologist specializing in migraine) at The Headache Center, part of the Neurology Center at the Scripps Hospital campus in Encinitas, California. Dr. Boyd will focus his time on developing additional cost effective treatment modalities and products for Therapeutic Solutions International, as well as ongoing clinical research.

Joining Dr. Boyd at TSI is Mr. Timothy Dixon, who was appointed as President and Chief Financial Officer of TSI. A long time associate of Dr. Boyd's, Mr. Dixon served as president of Splint Decisions. Mr. Gerry Berg resigned as Director and President effective March 31, 2011.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc. is a company whose business plan is focused on the development, production and marketing of cost effective technologies and therapeutic modalities for the treatment and prevention of common neurologic, sleep and temporomandibular disorders.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.